Helixmith Co. Ltd (084990) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Helixmith Co. Ltd (084990) has a cash flow conversion efficiency ratio of -0.013x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.87 Billion ≈ $-1.27 Million USD) by net assets (₩140.28 Billion ≈ $95.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 084990 equity to assets ratio to measure how much of total assets are equity-financed.
Helixmith Co. Ltd - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Helixmith Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Helixmith Co. Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Helixmith Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Helixmith Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zaklad Budowy Maszyn ZREMB-CHOJNICE S.A.
WAR:ZRE
|
0.014x |
|
Central Petroleum Ltd
AU:CTP
|
0.120x |
|
Elsoft Research Bhd
KLSE:0090
|
0.003x |
|
Global Menkul Degerler AS
IS:GLBMD
|
0.070x |
|
Key Tronic Corporation
NASDAQ:KTCC
|
-0.039x |
|
WM Technology Inc
NASDAQ:MAPS
|
0.047x |
|
Koss Corporation
NASDAQ:KOSS
|
-0.020x |
|
Global SM Tech Limited
KQ:900070
|
0.009x |
Annual Cash Flow Conversion Efficiency for Helixmith Co. Ltd (2010–2025)
The table below shows the annual cash flow conversion efficiency of Helixmith Co. Ltd from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see Helixmith Co. Ltd (084990) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩141.52 Billion ≈ $95.91 Million |
₩-6.90 Billion ≈ $-4.67 Million |
-0.049x | +58.59% |
| 2024-12-31 | ₩142.04 Billion ≈ $96.26 Million |
₩-16.72 Billion ≈ $-11.33 Million |
-0.118x | +30.11% |
| 2023-12-31 | ₩153.72 Billion ≈ $104.18 Million |
₩-25.89 Billion ≈ $-17.54 Million |
-0.168x | +10.38% |
| 2022-12-31 | ₩216.80 Billion ≈ $146.92 Million |
₩-40.74 Billion ≈ $-27.61 Million |
-0.188x | -10.96% |
| 2021-12-31 | ₩225.35 Billion ≈ $152.72 Million |
₩-38.16 Billion ≈ $-25.86 Million |
-0.169x | +2.54% |
| 2020-12-31 | ₩276.30 Billion ≈ $187.25 Million |
₩-48.01 Billion ≈ $-32.54 Million |
-0.174x | +17.25% |
| 2019-12-31 | ₩195.57 Billion ≈ $132.53 Million |
₩-41.07 Billion ≈ $-27.83 Million |
-0.210x | -108.92% |
| 2018-12-31 | ₩133.87 Billion ≈ $90.72 Million |
₩-13.46 Billion ≈ $-9.12 Million |
-0.101x | -538.11% |
| 2017-12-31 | ₩164.45 Billion ≈ $111.45 Million |
₩-2.59 Billion ≈ $-1.76 Million |
-0.016x | -9.76% |
| 2016-12-31 | ₩170.93 Billion ≈ $115.84 Million |
₩-2.45 Billion ≈ $-1.66 Million |
-0.014x | -188.31% |
| 2015-12-31 | ₩67.20 Billion ≈ $45.54 Million |
₩1.09 Billion ≈ $740.06K |
0.016x | +9598.28% |
| 2013-12-31 | ₩66.97 Billion ≈ $45.38 Million |
₩11.22 Million ≈ $7.60K |
0.000x | +100.30% |
| 2012-12-31 | ₩64.45 Billion ≈ $43.68 Million |
₩-3.58 Billion ≈ $-2.43 Million |
-0.056x | -26.50% |
| 2011-12-31 | ₩49.78 Billion ≈ $33.74 Million |
₩-2.19 Billion ≈ $-1.48 Million |
-0.044x | +12.11% |
| 2010-12-31 | ₩52.72 Billion ≈ $35.73 Million |
₩-2.64 Billion ≈ $-1.79 Million |
-0.050x | -- |
About Helixmith Co. Ltd
Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological… Read more